For one, I’m a bit taller than the average guy. My hair went silver earlier than I expected. And I’m fortunate that it’s easier for me to keep trim than a lot of people I know.
On the downside, I’ve got various allergies and genetic maladies that most folks don’t.
My environment isn’t average either. Here in Silicon Valley and the San Francisco Bay Area, I spend my days in some of the most polluted cities in the United States. Of course, in other ways, this region rates much higher than most of America.
Then there are my habits. For example, I eat well, but don’t get to the gym enough.
I bet you’re the same way – but different.
No one is average.
And that’s why it often seems like maintaining a healthy diet, getting plenty of exercise, and regular checkups just aren’t enough to keep us healthy. If it were, no one would gain too much weight, go bald at 30, or get cancer.
By our very nature, each of us is so unique that this one-size-fits-all approach just isn’t enough.
That’s what opened the door for an emerging field known as precision medicine. The idea here is to set up disease prevention and treatment measures for each and every individual, accounting for your genes, environment, and lifestyle… for my genes, environment, and lifestyle.
Think of it as a partnership – a “convergence” – among traditional medicine, molecular biology, data analysis, and cloud computing.
Doctors and other medical diagnosticians collect our info, and then feed it to the cloud. There software and data scientists can crunch through all that data – and then use what they turn up to prescribe precise disease treatments and preventative measures for each individual.
Mordor Intelligence has run the numbers – and says precision medicine will be worth $59.2 billion by 2021
The legal cannabis sector is no longer the “Wild West”-style marketplace it was back in, say, 2013, but there’s still plenty of volatility compared with the placid broader markets.
Then again, that’s why the right pot stocks reward forward-thinking investors with triple- and quadruple-digit gains. In fact, there’s a bevy of micro- and small-cap companies, any one of which could be the next mega-cap blockbuster – the long-sought-after “Starbucks of weed” or “Facebook of pot.”
My Nova-X Report’s Roadmap to Marijuana Millions model portfolio is chock-full of that kind of stocks. Right now my paid-up members are sitting on gains of 915%… 520.6%… 442.7%… and five more triple-digit winners. If you’d like to find out how to take advantage of this green revolution and get in on gains like those, click here.
But I don’t want to leave anyone with the impression that the only way to make a killing on pot stocks is to buy small, volatile companies. The gains from my Scotts Miracle-Gro Co. (NYSE: SMG) and GW Pharmaceuticals PLC (Nasdaq: GWPH) recommendations prove that just isn’t the case.
Then there’s the company I want to tell you about today.
It isn’t likely to quadruple your money quickly, but you’ll likely smash the market with double- and even triple-digit gains, and it pays a dividend that puts you way out ahead of inflation and low interest rates, too.
As the hardware chief at Facebook Inc. (Nasdaq: FB), Frankovsky’s team invented a way to use Blu-ray discs to save the oodles of photos that we all upload on that site every day. While Facebook still keeps its frequently accessed data on hard or flash drives, its deeper archives now reside on thousands of Blu-rays.
Frankovsky’s system – which involves robotic arms, thousands of discs, and hundreds of racks – turned out to be tremendously successful for the social-media giant. Facebook says the system cut costs by 50% and energy use by 80% compared to the hard disk drive system it was using.
So it’s no surprise that Frankovsky broke off from his “corporate overlords” back in 2014, opened up his own shop – Optical Archive Inc. – and started selling his system to other companies with Big Data storage needs.
If you’ve never heard of Frankovsky, that’s okay.
His beard may be a bit flamboyant – but he and Optical Archive operated in what I like to call “stealth mode”… quiet and under the radar.
But one once-struggling tech giant saw what was going on – and bought Frankovsky’s company in 2015.
That company was also operating in stealth mode at the time. After years of decline, it needed to stay quiet in order to rebuild.
In fact, around that time, it made three big stealth moves that have now put it back on the map.
It’s no longer in stealth mode… it’s absolutely crushing the market… and it’s just getting restarted.
Today I’ll tell you about the three big moves it made.
And I’ll show you how you can join in – and ride along as reclaims its place as one of the world’s preeminent technology companies.
Tension in the Middle East and the South China Sea… a political mess at home… sky-high stock prices.
And here’s something else to worry about…
On Nov. 1, a Wall Street Journal headline warned about the “Consumer Confidence Conundrum.”
Here’s the worry: According to WSJ writer Chris Dieterich and the folks he talked, because consumer confidence is at its highest level since December 2000, it’s time to “add this to the list of reasons investors ought to be getting nervous.”
The reason: It may signal the bull market is coming to an end.
Thanks to legal recreational use of marijuana about to launch in California and nationwide up in Canada, sometimes it’s easy to forget where we got started here.
Legal marijuana first came to my attention because of the “War on Pain.”
Let me explain…
In a study a year or so ago, the National Institutes of Health (NIH) found that about 11% of Americans suffered from debilitating pain. Other sources say the number of this country’s pain sufferers may run as high as 50 million.
But I don’t need statistics to know that millions of Americans suffer from serious pain problems.
I do so myself – and so do many of my friends and family members.
And that has turned the market for pain medication into a huge business. According to market researcher VisionGain, the worldwide business for pain drugs is worth about $68 billion right now.
Other studies say it’s even bigger.
Equally huge is the nation’s opioid crisis.
President Donald Trump has declared the opioid crisis a “public health emergency,” and a White House commission has released its final report on the epidemic, calling for more drug courts, greater training for doctors, and penalties for insurers who do not cover addiction treatment.
The number of opioid-related deaths rose 75%, from roughly 20,000 in 2010 to 35,000 in 2015. In other words, opioid-based drugs kill more than 100 Americans every day.
This surge in the number of pain sufferers – coupled with the snapback against the prescription of opioid drugs – has opened the door to a wholly new approach to pain treatment.
I’m talking about medical marijuana and all its derivatives.
The sort of number that doesn’t show up on anyone’s radar.
And now yours.
I’m talking about a tech sector whose overall sales grew 3.3% in the third quarter. True, that sounds meaningless – like something you wouldn’t want to invest in.
But I drilled down below the surface, and I found a lot of money to be made from this meager bounce.
Here’s the thing. It’s a small tick on the information technology (IT) services sector’s massive $3.5 trillion base.
When I look closer, I see that most of that growth – billions and billions of dollars of growth – is thanks to global corporations and other huge enterprises moving their IT services to the cloud. Doing that allows them to cut back spending on computer networks and makes it easier to add new services on the fly.
And it gives tech investors a target-rich environment.
So while others ignore the billions of dollars moving around in this often-forgotten part of the tech ecosystem, let’s look what I think will be a hugely profitable way to invest in this massive market.
It’s a company the mainstream financial media virtually ignores.
They may call it “weed,” but commercial legal cannabis – the “good stuff” – is more like a pampered, pedigreed dog.
Every pot grower knows that lots of care, technique, and technology goes into the cultivation and feeding of marijuana plants. All that’s needed so those plants can flower and produce commercially and medically useful compounds – especially the psychoactive tetrahydrocannabinol-9 (THC) that relieves pain and nausea and gets recreational users high.
This is seriously labor- and tech-intensive stuff. It’s also the specialty of the company I’m going to show you today.
Maybe Alphabet Inc. (Nasdaq: GOOGL) should have named its new smartphone the “Trojan Horse.”
See, there’s a lot more going on here than the introduction of a new piece of hardware.
Now then, don’t get me wrong. The Pixel 2 is an impressive device.
And on the surface, it seems designed to compete head-on with the iPhone from Apple Inc. (Nasdaq: AAPL). After all, it sports a state-of-the-art organic light-emitting diode (OLED) and comes in standard and plus sizes.
The Pixel 2 debuted two weeks ago along with several other pieces of hardware, including an updated laptop and an artificial intelligence-powered wearable camera. And the global leader in online search got generally great reviews for its new products.
However, I have to say the real star of the show received almost no attention.
It’s the hidden ingredient that is the true driving force behind these moves.